{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:19:18Z","timestamp":1760098758215},"reference-count":45,"publisher":"Elsevier BV","issue":"3-4","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JMV-Journal de M\u00e9decine Vasculaire"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jdmv.2024.08.001","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T11:28:43Z","timestamp":1724758123000},"page":"170-175","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unresolved questions on venous thromboembolic disease. Venous thromboembolism (VTE) management in obese patients. Consensus statement of the French Society of Vascular Medicine (SFMV)"],"prefix":"10.1016","volume":"49","author":[{"given":"S\u00e9bastien","family":"Miranda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolaine","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Gouin-Thibault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Espinasse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Mahe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"journal-title":"Cent Dis Control Prev","article-title":"Defining adult overweight and obesity","year":"2022","key":"10.1016\/j.jdmv.2024.08.001_bib0230"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0235","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.amjmed.2005.03.012","article-title":"Obesity as a risk factor in venous thromboembolism","volume":"118","author":"Stein","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0240","first-page":"42","article-title":"Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism","volume":"31","author":"Wilson","year":"2001","journal-title":"Haemostasis"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0245","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/bloodadvances.2019001373","article-title":"Comparing low-molecular-weight heparin dosing for treatment of venous thromboembolism in patients with obesity (RIETE registry)","volume":"4","author":"Mirza","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0250","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2141.2011.08826.x","article-title":"Anticoagulating obese patients in the modern era","volume":"155","author":"Patel","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0255","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1517\/14740338.2016.1120718","article-title":"The use of anticoagulants for the treatment and prevention of venous thromboembolism in obese patients: implications for safety","volume":"15","author":"Ihaddadene","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0260","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1055\/s-0037-1613090","article-title":"Dosing in heavy-weight\/obese patients with the LMWH, tinzaparin: a pharmacodynamic study","volume":"87","author":"Hainer","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0265","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thromres.2022.04.011","article-title":"Body weight adapted tinzaparin treatment in patients with obesity","volume":"214","author":"Pfrepper","year":"2022","journal-title":"Thromb Res"},{"year":"2023","series-title":"A multicentre prospective cohort study assessing the use of weight-adjusted low-molecular-weight-heparin in patients over 90\u00a0kg with acute cancer-associated venous thromboembolism","key":"10.1016\/j.jdmv.2024.08.001_bib0270"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0275","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/phar.1658","article-title":"Monitoring enoxaparin with antifactor Xa levels in obese patients","volume":"35","author":"Lee","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0280","first-page":"3","article-title":"Measuring anti-factor Xa activity to monitor low-molecular-weight heparin in obesity: a critical review","volume":"68","author":"Egan","year":"2015","journal-title":"Can J Hosp Pharm"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0285","first-page":"234","article-title":"An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin","volume":"37","author":"Favaloro","year":"2005","journal-title":"Pathology (Phila)"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0290","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1532\/LH96.05028","article-title":"How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective","volume":"11","author":"Favaloro","year":"2005","journal-title":"Lab Hematol"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0295","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0300","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11239-015-1315-2","article-title":"Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism","volume":"41","author":"Smythe","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0305","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1345\/aph.1L194","article-title":"Anticoagulation: low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings","volume":"43","author":"Nutescu","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0310","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/0003-4819-134-3-200102060-00009","article-title":"Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease","volume":"134","author":"Merli","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0315","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/j.1538-7836.2007.02565.x","article-title":"Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials","volume":"5","author":"Davidson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0320","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial","volume":"140","author":"B\u00fcller","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0325","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"B\u00fcller","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0330","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.thromres.2021.10.009","article-title":"Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: drug levels and clinical outcomes","volume":"208","author":"Ballerie","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0335","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11239-020-02199-0","article-title":"Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data","volume":"51","author":"Costa","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0340","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.thromres.2019.08.021","article-title":"Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs","volume":"182","author":"Spyropoulos","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0345","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s11239-022-02661-1","article-title":"Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States","volume":"54","author":"Berger","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0350","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11239-022-02668-8","article-title":"Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism","volume":"54","author":"Novak","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0355","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1160\/th15-06-0474","article-title":"Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists","volume":"115","author":"Di Nisio","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0360","doi-asserted-by":"crossref","first-page":"00554","DOI":"10.1183\/23120541.00554-2020","article-title":"Direct oral anticoagulant therapy in patients with morbid obesity after intermediate- or high-risk pulmonary emboli","volume":"7","author":"Lachant","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0365","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/jcm10020200","article-title":"Effectiveness and safety of apixaban vs. warfarin in venous thromboembolism patients with obesity and morbid obesity","volume":"10","author":"Cohen","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0370","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12872-023-03067-4","article-title":"Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis","volume":"23","author":"Park","year":"2023","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0375","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"Martin","year":"2021","journal-title":"J Thromb Haemost"},{"year":"2022","series-title":"REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism. The RENOVE open-label, randomized, controlled trial","key":"10.1016\/j.jdmv.2024.08.001_bib0380"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0385","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.amjmed.2016.12.033","article-title":"Oral anticoagulant use after bariatric surgery: a literature review and clinical guidance","volume":"130","author":"Martin","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0390","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.soard.2021.12.023","article-title":"The APB study: apixaban pharmacokinetics in bariatric patients before to 1 year after vertical sleeve gastrectomy or Roux-en-Y gastric bypass","volume":"18","author":"Steele","year":"2022","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0395","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s11695-021-05814-y","article-title":"Anti-Xa levels in morbidly obese patients using apixaban or rivaroxaban, before and after bariatric surgery","volume":"32","author":"Kok","year":"2022","journal-title":"Obes Surg"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0400","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/bloodadvances.2021006696","article-title":"Direct oral Xa inhibitors for the treatment of venous thromboembolism after bariatric surgery","volume":"7","author":"Kushnir","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0405","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.thromres.2009.02.003","article-title":"Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients","volume":"125","author":"Rondina","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0410","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/8755122515617200","article-title":"Low-molecular-weight heparin prophylaxis dosing: is weight an issue?","volume":"32","author":"Minze","year":"2016","journal-title":"J Pharm Technol"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2020.11.021","article-title":"Weight-adjusted tinzaparin for venous thromboembolism prophylaxis in bariatric surgery patients weighing 160\u00a0kg or more","volume":"198","author":"Li","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0420","doi-asserted-by":"crossref","first-page":"100054","DOI":"10.1016\/j.rpth.2023.100054","article-title":"Weight-adjusted dosing of tinzaparin for thromboprophylaxis in obese medical patients","volume":"7","author":"Pfrepper","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0425","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1310\/hpj4908-740","article-title":"Appropriate enoxaparin dose for venous thromboembolism prophylaxis in patients with extreme obesity","volume":"49","author":"Shelkrot","year":"2014","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0430","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1381\/096089202321144522","article-title":"A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery","volume":"12","author":"Scholten","year":"2002","journal-title":"Obes Surg"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0435","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/ajh.23228","article-title":"Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity","volume":"87","author":"Freeman","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0440","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamasurg.2013.72","article-title":"Pharmacologic and mechanical strategies for preventing venous thromboembolism after bariatric surgery: a systematic review and meta-analysis","volume":"148","author":"Brotman","year":"2013","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0445","first-page":"799","volume":"19","author":"Giannopoulos","year":"2023","journal-title":"Venous thromboembolism (VTE) prophylaxis after bariatric surgery: a national survey of MBSAQIP director practices. Surg Obes Relat Dis"},{"key":"10.1016\/j.jdmv.2024.08.001_bib0450","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/EJA.0000000000000729","article-title":"European Guidelines on perioperative venous thromboembolism prophylaxis: executive summary","volume":"35","author":"Afshari","year":"2018","journal-title":"Eur J Anaesthesiol"}],"container-title":["JMV-Journal de M\u00e9decine Vasculaire"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542451324001366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542451324001366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T19:50:33Z","timestamp":1726429833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542451324001366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":45,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2542451324001366"],"URL":"https:\/\/doi.org\/10.1016\/j.jdmv.2024.08.001","relation":{},"ISSN":["2542-4513"],"issn-type":[{"type":"print","value":"2542-4513"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unresolved questions on venous thromboembolic disease. Venous thromboembolism (VTE) management in obese patients. Consensus statement of the French Society of Vascular Medicine (SFMV)","name":"articletitle","label":"Article Title"},{"value":"JMV-Journal de M\u00e9decine Vasculaire","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdmv.2024.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}